Search tips
Search criteria 


Logo of aryaathArchiveInstruction for AuthorsSubmit OnlineCurrent IssueSearchFarzanegan Radandish Co.
ARYA Atheroscler. 2010 Summer; 6(2): 78–81.
PMCID: PMC3347814

Some Notes on Stem Cell Therapy in Cardiovascular Diseases


Cardiovascular diseases have become an increasing clinical issue worldwide. Acute ischaemic injury and chronic cardiomyopathies lead to permanent loss of cardiac tissue and ultimately heart failure. Current therapies widely aim to attenuate the pathological changes that occur after injury and to reduce risk factors of cardiovascular diseases. However, they do not improve the patient's quality of life or the prognosis more than moderate. A new challenge in the treatment of the cardiovascular disease is cellular transplantation or cellular cardiomyoplasty. Different types of stem cells have been used for stem cell therapy. Clinical trials using primary bone-marrow-derived cells and skeletal myoblasts have also shown some encouraging results. An additional clinical and pre-clinical study to further enhance the beneficial effects of cell therapy is necessary. Recent studies have shown that there are various pools of putative resident stem cells in an adult heart, raising the hope that these cells can contribute to the treatment of cardiovascular diseases.

Keywords: Stem Cell Therapy, Cardiovascular Disease, Iran


Cardiovascular disease is one of the major causes of death worldwide accounting for nearly 17 million deaths per annum according to the World Health Organization Atherosclerosis is a complex trait which arises from the interaction of a number of genetic and environmental factors and complex gene-environment interactions.1

Atherosclerosis involves multiple vascular territories such as carotids, coronaries and peripheral vessels. The molecular mechanisms leading to atherosclerosis are still unclear.1 Many epidemiological studies indicated that hypertension, diabetes, obesity, smoking and hyperlipidaemia are risk factors contributing to coronary artery diseases (CAD).24 For those suffering from cardiovascular diseases, stem cell biology represents a new medical frontier. Researchers are working towards using stem cells to replace damaged heart cells and restore cardiac function. Although there is much excitement because researchers nowknow that adult and embryonic stem cells can repair damaged heart tissue, many questions remained to be answered before clinical applications can be made. Unlike other organs such as liver, heart lacks adequate auto-regeneration ability.5 There are several therapies for heart failure including medical, surgical and stem cell or progenitor cell therapy. Cell therapy has become a new potential cardiovascular therapeutical tool recently.6 The effective goals of cell therapy are myocardial regeneration and neovascularisation. Several different types of stem cells have been studied to find the best source for cardiac regeneration (figure 1).

Figure 1
Stem cell therapy for cardiovascular disease. (Figure design By Arlen Mokhtarzadeh)

Stem cell populations for cardiovascular disease

Embryonic stem cells (ESCs)

Embryonic stem cells in mouse and human can be extracted from the inner body of the blastocyst and can be cultured in vitro.7, 8 From the various stem cell populations studied so far, the ESC cells have the greatest capacity for cardiac cell differentiation and long-term survival.9 However, no clinical trial in human for myocardial repair has been applied yet.

Skeletal myoblasts

Skeletal myoblasts which are called satellite cells or skeletal muscle precursors are present in skeletal muscles. These cells are further differentiated than the ESCs. After two or three weeks of cell culture, they can be implanted.10 Skeletal myoblasts have the capacity to differentiate in vitro into non-muscle cell types.11, 12 Finally, there are several barriers that still remain including variability and complexity in the application of skeletal myoblast populations.13

Bone-marrow-derived stem cells

Bone marrow mononuclear cell can be derived from bone marrow and peripheral blood. Easy isolation, safety and feasibility for their implantation are the advantages to consider, although, investigations found limited or no differentiation of bone marrow cells to cardiovascular cell types.14, 15 Endothelial progenitor cells (EPCs) is another bone marrow cell type which is important in neovasculogenesis.

Mesenchymal stem cells (MSCs)

Mesenchymal stem cells derive from bone marrow and adipose tissue. It is easy to isolate and culture these cells in vitro. The MSCs are multipotent and they are less-immunogenic than others.16 A problem with mesenchymal stem cell engraftment was formation of bone and cartilage in heart after transplantation. The microenvironment at the region of engraftment of stem cells is very important and it may cause differentiation of stem cells into unwanted cell types

Important parameters in cell therapy

In order to consider cell therapy as clinically relevant, many parameters need to be optimized including cell type, cell function, cell number and route of administration. As mentioned earlier about different cell types for cell therapy, in all controlled studies, significant positive results have been observed in multipotent cells which were transplanted.1719 The cell numbers used in cell therapy for chronic coronary artery disease can be between 3.106 to 800.106 cells. There is no certain correlation between the number of cells administered and its effect on heart failure. Another parameter that is associated with cell therapy improvement is the cell functionality.20, 21 Route of administration which considered in surveys is not a determining factor for successive delivery, although there is no direct comparison between routs of administration in cell therapy for cardiovascular diseases.

Mechanism of Cell Therapy

These different stem cell types have different potential mechanisms of action. One of the proposed mechanisms is myogenesis which is more controversial than the other mechanism, particularly in transdifferentiation of bone marrow derived cells into heart cells. It is not yet clear if transplanted cells themselves differentiate or paracrine effects of the transplanted cells stimulate stem cells differentiation or both of these factors act. The other proposed mechanism of cell therapy is angiogenesis. Bone marrow cells may be able to secret multiple angiogenic substances and these cells can be differentiated into cells with the ability to create new blood vessels. Strategies to augment cell function, survival, and homing could be crucial to improve success rates for cell therapy. There are two strategies which may improve the efficiency of cell therapy: 1) pretreatment of the cells ex vivo by small molecules or modification of the cells by genes to improve the function, survival, and homing capacity after infusion or injection; and 2) activation of the target tissue to specifically augment signals capable of attracting infused cells or modulating cell function and survival.22 Researchers studying the use of embryonic stem cells are also trying to determine why, in animals, most implanted stem cells re-enter the circulation or die rather than engraft to the heart muscle wall to form new muscle cells. They are also searching for the ways to use gene therapy to increase the number of embryonic stem cells that live on as new muscle cells.

Stem cell research in Iran

In the Middle East, the highest absolute number of patients with cardiovascular disease is estimated in Iran. While combating major risk factors including hypertension, smoking, and hyperlipidemia, is crucial for improving health of the nation, control programs regarding CAD, via modifying the modifiable risk factors are envisaged.23 Several stem cell therapies have been performed in Iran. In a survey in Iran the efficacy of autologous bone marrow derived mesenchymal stem cells in improving heart function in patients with old myocardial infarction was investigated.24 In another study in Iran by Ghavamzadeh et al, hematopoietic stem cell therapy was reported to be a choice treatment of many malignant, non-malignant, and genetic diseases. They introduced 105 cellular therapies for post-myocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, and renal cell carcinoma. About 30 patients were re-transplanted and about 74.9% of the patients remained alive between one to 168 months after stem cell transplantation. Nearly 25.1% of their patients died after stem cell transplantation. The causes of deaths were relapse, infections, hemorrhagic cystitis, graft versus host disease, and others.25


Several phenotypically distinct cell populations have been utilized for heart failure. In summary, pluripotent (e.g., mesenchymal stem cells), totipotent (e.g., embryonic) and multipotent (e.g., tissue specific) stem cells can be applied.26 Multipotent stem cells have less ability to differentiate than embryonic stem cells, but embryonic stem cells are able to differentiate into cardiomyocytes.27, 28 In several studies, it has been shown that several pluripotent stem cells are able to differentiate into cardiomyocytes and lead to neovascularisation such as haematopoietic, mesenchymal and endothelial progenitor stem cells.2932 Many researchers now believe that cellular therapy will likely revolutionize approaches to heart failure.

Future perspectives

Finally, proper cell type, cell number and route of administration still need to be determined and generation of unwanted cell types must be prevented. Researchers have to determine exactly how the stem cells work. The main challenge for developing any stem cell based therapy for heart diseases is the control of cell migration, proliferation and differentiation ex vivo as well as in vivo. The initial trials with patients will be phase I studies. However, the validity for the future of stem cell therapy depends on the benefits obtained in the human phase II and III clinical trials. Stem cell therapy for heart failure needs further investigation and much more work needs to be done. Stem cell therapies in conjunction with current treatments may help improve the quality of life in cardiovascular disease patients.

Conflict of Interests

Authors have no conflict of interests.


1. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–4. [PMC free article] [PubMed]
2. Gotto AM., Jr Interactions of the major risk factors for coronary heart disease. Am J Med. 1986;80(2A):48–55. [PubMed]
3. Kannel WB. Clinical misconceptions dispelled by epidemiological research. Circulation. 1995;92(11):3350–60. [PubMed]
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47. [PubMed]
5. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344(23):1750–7. [PubMed]
6. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest. 2005;115(3):572–83. [PMC free article] [PubMed]
7. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154–156. [PubMed]
8. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7. [PubMed]
9. van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, Freund C, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007;1(1):9–24. [PubMed]
10. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest. 1996;98(11):2512–23. [PMC free article] [PubMed]
11. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol. 2003;41(5):879–88. [PubMed]
12. Asakura A, Komaki M, Rudnicki M. Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation. 2001;68(4–5):245–53. [PubMed]
13. Deasy BM, Lu A, Tebbets JC, Feduska JM, Schugar RC, Pollett JB, et al. A role for cell sex in stem cell-mediated skeletal muscle regeneration: female cells have higher muscle regeneration efficiency. J Cell Biol. 2007;177(1):73–86. [PMC free article] [PubMed]
14. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428(6983):668–73. [PubMed]
15. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428(6983):664–8. [PubMed]
16. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418(6893):41–9. [PubMed]
17. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003;361(9351):45–6. [PubMed]
18. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23):2775–83. [PubMed]
19. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1199–209. [PubMed]
20. Rouy D, Lebrun F, Berchem G, Delagardelle C, Beissel J, Wagner DR. Cell therapy for severe chronic heart failure: the Luxembourg experience. Biomed Mater Eng. 2008;18(1 Suppl):S27–S31. [PubMed]
21. Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD registry. Circ Res. 2007;100(8):1234–41. [PubMed]
22. Seeger FH, Zeiher AM, Dimmeler S. Cell-enhancement strategies for the treatment of ischemic heart disease. Nat Clin Pract Cardiovasc Med. 2007;4(Suppl 1):S110–S113. [PubMed]
23. Gasparyan AY, Mohammad-Hasani MR, Hassoun H, Darban H. Recent advances in cardiovascular medicine: the tenth Iranian congress on cardiovascular update. Arch Iran Med. 2009;12(2):213–16. [PubMed]
24. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, Sanatkar M, Gasemi M, Mirkhani H, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med. 2007;10(4):467–73. [PubMed]
25. Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Iravani M, Bahar B, et al. Stem cell transplantation; Iranian experience. Arch Iran Med. 2009;12(1):69–72. [PubMed]
26. Fijnvandraat AC, Moorman AF. Stem cells: biology and possible application to myocardial infarct. Ned Tijdschr Geneeskd. 2004;148(24):1186–91. [PubMed]
27. Caspi O, Huber I, Kehat I, Habib M, Arbel G, Gepstein A, et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol. 2007;50(19):1884–93. [PubMed]
28. Gepstein L. Derivation and potential applications of human embryonic stem cells. Circ Res. 2002;91(10):866–76. [PubMed]
29. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701–5. [PubMed]
30. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93–8. [PubMed]
31. Atsma DE, Fibbe WE, Rabelink TJ. Opportunities and challenges for mesenchymal stem cell-mediated heart repair. Curr Opin Lipidol. 2007;18(6):645–9. [PubMed]
32. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107(24):3093–100. [PubMed]

Articles from ARYA Atherosclerosis are provided here courtesy of Farzanegan Radandish Co.